Back to Sites Chiangrai Prachanukroh Hospital Site Number 5116 Address Chiang Rai Regional Hosp. CRS Chiangrai Prachanukroh Hospital 1039 Sathanpayaban Road Chiang Rai, Chiang Rai 57000 Thailand IMPAACT Members at this Site Suree KaewPanan CAB Member Wannipha Yenjal Clinical Research Assistant Pra-ornsuda Sukrakanchana CRS Coordinator Tim Cressey CRS Leader Gonzague Jourdain CRS Leader Pacharee Kantipong CRS Leader Jane Bupp DAIDS PO Jullapong Achalapong Investigator Chulapong Chanta Investigator Rawiwan Hansudewechakul Investigator Pradthana Ounchanum Investigator Supaporn Utsaha Investigator Chaiporn Kamluang Local Laboratory Yupawan Thaweesombat Pharmacist of Record Ruethai Wongchai Research Assistant Sangdao Somsri Staff Suporn Watanaporn Staff Chaniporn Yodsuwan Study Coordinator Studies at this Site IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling